QIA.DE
Latest Trade
30.60EURChange
-0.12(-0.39%)Volume
1,096,581Today's Range
-
30.7552 Week Range
-
37.03As of on the XETRA ∙ Minimum 15 minute delay
Previous Close | 30.72 |
|---|---|
Open | 30.74 |
Volume | 1,096,581 |
3M AVG Volume | 8.40 |
Today's High | 30.75 |
Today's Low | 30.43 |
52 Week High | 37.03 |
52 Week Low | 29.01 |
Shares Out (MIL) | 226.97 |
Market Cap (MIL) | 7,054.59 |
Forward P/E | 23.93 |
Dividend (Yield %) | -- |
Qiagen Announces Change In Global Sales Structure
Qiagen Affirms Q2 Results
Qiagen Says Total Net Sales Rose 1% To $381.6 Mln In Q2 Of 2019
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Industry
Biotechnology & Drugs
Executive Leadership
Hakan Bjorklund
Independent Chairman of the Supervisory Board
Peer M. Schatz
Managing Director, Chief Executive Officer, Member of the Executive Committee
Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Committee
Barthold Piening
Senior Vice President, Head of Global Operations, Member of the Executive Committee
Annette Koch
Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee
Price To Earnings (TTM) | 42.09 |
|---|---|
Price To Sales (TTM) | 5.16 |
Price To Book (MRQ) | 2.94 |
Price To Cash Flow (TTM) | 19.41 |
Total Debt To Equity (MRQ) | 67.10 |
LT Debt To Equity (MRQ) | 53.63 |
Return on Investment (TTM) | 4.28 |
Return on Equity (TTM) | 3.56 |
The following are some of the factors that may move German stocks on Thursday:
The following are some of the factors that may move German stocks on Monday:
Laboratory Corporation of America Holdings:
* FDA- ALSO APPROVED COMPANION DIAGNOSTIC TEST, THERASCREEN PIK3CA RGQ PCR KIT, TO DETECT PIK3CA MUTATION IN A TISSUE AND/OR A LIQUID BIOPSY Source text for Eikon: Further company coverage:
The following are some of the factors that may move German stocks on Tuesday:
The following are some of the factors that may move German stocks on Monday:
The following are some of the factors that may move German stocks on Monday:
The following are some of the factors that may move German stocks on Thursday:
The Swiss blue-chip SMI was seen opening down percent 0.33 percent at 9,294 points on Friday, according to premarket indications by bank Julius Baer.
* QIAGEN AND TECAN ANNOUNCE COLLABORATION TO STREAMLINE PREANALYTICAL PROCESSING OF QUANTIFERON-TB GOLD PLUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
The following are some of the factors that may move German stocks on Tuesday:
The following are some of the factors that may move German stocks on Tuesday:
The following are some of the factors that may move German stocks on Monday:
The following are some of the factors that may move German stocks on Thursday:
The following are some of the factors that may move German stocks on Tuesday:
The following are some of the factors that may move German stocks on Friday:
* QIAGEN ANNOUNCES NEW COLLABORATION TO DEVELOP COMPANION DIAGNOSTIC TO GUIDE TREATMENT FOR PATIENTS WITH PIK3CA-MUTATED ADVANCED BREAST CANCER
Belgian drugmaker UCB <UCB.BR> expects to invest about 1 billion pounds in Britain over the next five years, throwing its support behind the country's life sciences sector despite Brexit uncertainty.
* BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS DEAL UPSIZED TO $500M; BOOKS TO CLOSE AT 13.30 UK Source text for Eikon: Further company coverage:
The following are some of the factors that may move German stocks on Tuesday:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.